Pharmaceutical manufacturers of Amoxicillin

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

Founded in 1986 by Mr. P. V. Ramprasad Reddy, Mr. K. Nityananda Reddy and a small group of highly committed professionals, Aurobindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillins, it has a presence in key therapeutic segments such as neurosciences, cardiovascular, anti-retrovirals, anti-diabetics, gastroenterology and anti-biotics, among others.

We represent Lunan Pharmaceutical Group, a joint venture based in China, specialized in the production and exportation of APIs and finished medications. The consortium consists of seven affiliated firms, including Lunan Hope Pharmaceutical Co., LTD., Lunan Better Pharmaceutical Co., LTD., Shandong New Time Pharmaceutical Co., LTD., and Lunan New Time Bio-Tech Co., LTD., among others

Inner Mongolia Changsheng Pharmaceutical Co., Ltd. was established in the year 2003. The company is mainly engaged in the production and sale of APIs. The products made on the site include Amoxicillin, ampicillin, piperacillin, 6-aminopenicillanic acid, penicillin G potassium, and sulbactamic acid. Changsheng Pharma is accredited and approved by China NMPA, EDQM etc. for GMP compliance.

Reyoung Pharmaceutical Co., Ltd., established in 1966, is a modern comprehensive pharmaceutical company. Reyoung is given the title of National Trustworthy Company for Contract and Credit, Grade AAA Credit Company and Credit Company of Shandong Medical Industry. In the past 50 years, Reyoung inherits the mission “Reyoung Pharma., Benefit the public”, insists the business concept “Innovation is the basis, Product quality is first”. Never stop exploration and innovation, forging ahead with determination, and realizing the sustainable healthy development.

Kopran Ltd is a globally operating pharmaceutical company focused on marketing and production. The company possesses two WHO GMP approved manufacturing facilities. Their FDF facility in Khopoli is accredited by TGA, MHRA, and MCC, while their API facility in Mahad holds WHO GMP accreditation. Kopran Ltd exports its products to prominent markets in Europe, Southeast Asia, and Latin America. The company offers a diverse range of Active Pharmaceutical Ingredients (APIs) in categories such as Anti-hypertensive, Macrolides, Neuromodulator, Cephalosporins, Carbapenems, and Oncology, as well as Finished Dosage Forms in Carbapenems, Gastroenterology, Anthelmintics, Central Nervous System, Pain management, Anti-allergies, Anti-asthmatics, Anti-Infectives, Penicillins, Cardiovascular, Antiprotozoal, Oncology, Anti-Diabetics, Erectile Dysfunction, and Macrolides.

Sun Pharma is a global, comprehensive, specialized pharmaceutical company with production facilities for API and FDF in India, the United States, Latin America, and Europe. It produces and sells a wide range of pharmaceutical formulations as branded generics and generic drugs in India, the US, and various other global markets. It is supported by 2 advanced R&D Centers with a team of over 600 scientists for projects in Chemical Synthesis, Clinical Research, and formulation development. Sun is a frontrunner in specific therapy areas and possesses robust expertise in product development, process chemistry, and manufacturing.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

ACS DOBFAR, an Italian firm established in 1973, is a privately owned business that serves as a fully integrated producer of Cephalosporin and Penicillin APIs as well as Finished Dosage Formulations. With manufacturing facilities located across the globe routinely examined by the US FDA, it stands as a prominent company among suppliers to the US market.

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Greetings, we are Sandoz B2B. As a division of Sandoz, we are completely dedicated to ensuring availability of cost-effective medication for everyone. We distribute high-quality medication globally through close collaboration with pharmaceutical partners. Whether it involves active pharmaceutical ingredients, finished dosage products, or comprehensive end-to-end CDMO solutions, we are here for you.

NCPC International Corp. is a platform for international trade of NCPC and the exclusive channel for exporting the preparations of NCPC, the business scope covers import and export trade, CMO, technology transfer and pharmaceutical logistics in domestic. NCPC International Corp. provides all-around and one-stop sales and service on APIs, preparations, medical equipments and consumables, based on creating more values for foreign customers. NCPC International Corp. has been exporting to more than 80 countries and regions, increasing the overseas sales yearly, ranking 1st on exporting preparations in china mainland for last continuous 3 years. NCPC International Corp. is a worldwide supplier of generic pharmaceuticals. As an Anti-infective expert and your local one- stop partner NCPC International Corp. will provide you the most comprehensive products and the most professional and efficient services. We are sincerely expecting to cooperate with friends from all sectors for shared development and a brighter future!

Nectar Lifesciences Limited is a research-driven, leading manufacturer of Active Pharmaceutical Ingredients (API), intermediates as well as Finished dosage forms offering largest segment of anti-infectives namely Cephalosporins. Nectar has proven to be a reliable CMO to global pharma innovators.

Akums is a research-oriented, fully integrated firm specializing in the production, manufacturing, and distribution of APIs and intermediates. Akums has positioned itself as a top manufacturer of generic pharmaceuticals based in India, serving customers in more than 51 nations. It operates a dedicated facility for personalized research and synthesis. Akums' production units are located at three different sites in two states of India. Its strict protocols and processes guarantee compliance with all regulatory standards, environmental norms, and technological advancements. Akums holds certifications from EU-GMP, KFDA, WHO-GMP, and PMDA.

Established in 1993, SUANFARMA is a business-to-business partner in the field of life sciences specializing in the formulation, manufacture, and marketing of components for the pharmaceutical, veterinary, and nutraceutical sectors. In SUANFARMA, we provide our CDMO capabilities for fermentation and chemical synthesis projects, delivering a comprehensive service with a proven track record, facilitating success in the formulation, expansion, production, and marketing of an API, whether it is innovative or generic

Sinopharm, a significant healthcare organization affiliated with the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council, operates with a workforce of 128,000 and a comprehensive industry presence encompassing research and development, production, supply chain management, retail outlets, medical services, engineering, events, international trade, and financial services. It possesses more than 1,100 subsidiaries and 6 publicly traded companies, including Sinopharm Group Co., Ltd. (Sinopharm Holding), China National Medicines Corporation Ltd., and China National Accord Medicines Corporation Ltd.